Sofiva Genomics Co., Ltd. Statistics
Sofiva Genomics Co., Ltd. (6615) Stock Statistics & Valuation Metrics
Total Valuation
Sofiva Genomics Co., Ltd. has a market cap or net worth of TWD 708.26M. The enterprise value is TWD 689.31M.
- Market Cap
- TWD 708.26M
- Enterprise Value
- TWD 689.31M
Share Statistics
Sofiva Genomics Co., Ltd. has 21,593,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 21,593,400
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Sofiva Genomics Co., Ltd.’s return on equity (ROE) is -0.01 and return on invested capital (ROIC) is -5.06%.
- Return on Equity (ROE)
- -0.01
- Return on Assets (ROA)
- -0.01
- Return on Invested Capital (ROIC)
- -5.06%
- Return on Capital Employed (ROCE)
- -0.05
- Revenue Per Employee
- 25.71M
- Profits Per Employee
- -624.00K
- Employee Count
- 15
- Asset Turnover
- 0.53
- Inventory Turnover
- 8.22
Valuation Ratios
The current PE Ratio of Sofiva Genomics Co., Ltd. is 49.47. Sofiva Genomics Co., Ltd.’s PEG ratio is 0.22.
- PE Ratio
- 49.47
- PS Ratio
- 1.86
- PB Ratio
- 1.10
- Price to FCF
- 25.73
- Price to Operating Cash Flow
- 23.43
- PEG Ratio
- 0.22
Income Statement
In the last 12 months, Sofiva Genomics Co., Ltd. had revenue of 385.71M and earned -9.36M in profits. Earnings per share was -0.43.
- Revenue
- 385.71M
- Gross Profit
- 99.13M
- Operating Income
- -33.74M
- Pretax Income
- -8.30M
- Net Income
- -9.36M
- EBITDA
- 7.87M
- Earnings Per Share (EPS)
- -0.43
Cash Flow
In the last 12 months, operating cash flow was 30.38M and capital expenditures -2.98M, giving a free cash flow of 27.40M billion.
- Operating Cash Flow
- 30.38M
- Free Cash Flow
- 27.40M
- Free Cash Flow per Share
- 1.26
Dividends & Yields
Sofiva Genomics Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 0.91%
- Dividend Per Share
- ―
- Dividend Yield
- 0.91%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 3.89%
- Earnings Yield
- 2.07%
Stock Price Statistics
- Beta
- 0.19
- 52-Week Price Change
- 4.46%
- 50-Day Moving Average
- 33.49
- 200-Day Moving Average
- 34.04
- Relative Strength Index (RSI)
- 41.79
- Average Volume (3m)
- 12.08K
Important Dates
Sofiva Genomics Co., Ltd. upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 12, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Sofiva Genomics Co., Ltd. as a current ratio of 3.33, with Debt / Equity ratio of 5.66%
- Current Ratio
- 3.33
- Quick Ratio
- 2.84
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -7.00
- Interest Coverage Ratio
- -39.83
Taxes
In the past 12 months, Sofiva Genomics Co., Ltd. has paid 551.00K in taxes.
- Income Tax
- 551.00K
- Effective Tax Rate
- -0.07
Enterprise Valuation
Sofiva Genomics Co., Ltd. EV to EBITDA ratio is 12.23, with an EV/FCF ratio of 23.57.
- EV to Sales
- 1.70
- EV to EBITDA
- 12.23
- EV to Free Cash Flow
- 23.57
- EV to Operating Cash Flow
- 21.26
Balance Sheet
Sofiva Genomics Co., Ltd. has TWD 131.52M in cash and marketable securities with TWD 38.30M in debt, giving a net cash position of TWD 93.22M billion.
- Cash & Marketable Securities
- TWD 131.52M
- Total Debt
- TWD 38.30M
- Net Cash
- TWD 93.22M
- Net Cash Per Share
- TWD 4.32
- Tangible Book Value Per Share
- TWD 29.41
Margins
Gross margin is 26.56%, with operating margin of 3.55%, and net profit margin of 3.88%.
- Gross Margin
- 26.56%
- Operating Margin
- 3.55%
- Pretax Margin
- 4.87%
- Net Profit Margin
- 3.88%
- EBITDA Margin
- 13.92%
- EBIT Margin
- 5.67%
Analyst Forecast
The average price target for Sofiva Genomics Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -6.67%
- EPS Growth Forecast
- ―
